Clinical Course of Early Onset Prostate Cancer with Special Reference to Family History as a Prognostic Factor (original) (raw)
Article navigation
Research Articles| July 01 1998
Search for other works by this author on:
c Oncology, Lund University Hospital, Lund and
Search for other works by this author on:
d Department of Surgery, Helsingborg County Hospital, Helsingborg, Sweden
Search for other works by this author on:
European Urology (1998) 34 (1): 19–24.
Abstract
Objective: The aim of this study was to describe the clinical characteristics of early onset prostate cancer, with special reference to family history as a possible prognostic factor. Material and Methods: We identified all cases of prostate cancer diagnosed before the age of 51 in the Southern health care region in Sweden between 1958 and 1994. Clinical data were collected retrospectively from medical records. Data about family history of prostate cancer were also collected from the parish authorities and the Regional Cancer Registry. Results: In all, 89 cases were included. The median time of follow-up was 17 years. During the time of follow-up, 65 patients died, 57 of whom died from prostate cancer. At diagnosis, 34% of the patients had localized, 22% had locallly advanced, and 40% had metastatic tumours. The tumours were well differentiated in 30% of the cases, moderately differentiated in 38%, and poorly differentiated in 28%. Information on tumour grade and stage was missing in 3 cases. The cause-specific survival was 48% at 5 years and 29% at 10 years. The 18 patients with a family history of prostate cancer had a somewhat better prognosis than the patients with a negative family history, though the difference did not reach statistical significance (p = 0.08). Conclusions: Early onset prostate cancer is a serious disease with high mortality. The proportions of patients with poorly differentiated and metastatic tumours appeared to be larger than for cases diagnosed later in life, but this could be explained by selection bias since younger men may have a lower probability of having asymptomatic localized tumours diagnosed. Family history of prostate cancer was not significantly associated with prognosis.
References
Wilson JM, Kemp IW, Stein GJ: Cancer of the prostate. Do younger men have a poorer survival rate? Br J Urol 1984;56–59:391.
Johnson DE, Lanieri JP, Ayala AG: Prostatic adenocarcinoma occurring in men under 50 years of age. J Surg Oncol 1972;4:207–216.
Grönberg H, Damber J-E, Jonsson H, Lenner P: Patient age as a prognostic factor in prostate cancer. J Urol 1994;152:892–895.
Adami H-O, Norlén BJ, Malker B, Meirik O: Long-term survival in prostatic carcinoma, with special reference to age as a prognostic factor. Scand J Urol Nephrol 1986;20:107–112.
Carter BS, Beaty TH, Steinberg GD, Childs B, Walsh PC: Mendelian inheritance of familial prostate cancer. Proc Natl Acad Sci USA 1992;89:3367–3371.
Smith JR, Freije D, Carpten JD, et al: Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science 1996;274:1371–1374.
Kupelian P, Kupelian V, Witte J, Macklis R, Klein E: Family history of prostate cancer in patients localized prostate cancer: An independent predictor of treatment outcome. J Clin Oncol 1997;15:1478–1480.
Johansson J-E, Holmberg L, Johansson S, Bergström R, Adami H-O: Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA 1997;227:467–471.
Aprikian AG, Zhang Z-F, Fair WR: Prostate adenocarcinoma in men younger than 50 years. Cancer 1994;74:1768–1777.
Bratt O, Kristoffersson U, Lundgren R, Olsson H: Sons of men with prostate cancer: Their attitudes regarding possible inheritance of prostate cancer, screening, and genetic testing. Urology 1997;50:360–365.
Stenbeck M, Holm L-E: Cancer survival in Sweden in 1961–91. Male genital organs. Acta Oncol 1995;34(suppl 4):61–66.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
Sign in
Digital Version
Pay-Per-View Access
$45.00
1 Karger Article Bundle Token
$170
Rental
This article is also available for rental through DeepDyve. 